SCHEMBL716168

SCHEMBL716168

Cc1ccc(NC(=O)c2ccncc2)cc1Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 12/20 0.75
BCR P11274 11/20 0.75
PDGFRB P09619 6/20 0.75
HDAC3 O15379 2/20 0.75
KDR P35968 2/20 0.75
HDAC4 P56524 2/20 0.75
HDAC1 Q13547 2/20 0.75
HDAC7 Q8WUI4 2/20 0.75
HDAC2 Q92769 2/20 0.75
HDAC10 Q969S8 2/20 0.75
HDAC11 Q96DB2 2/20 0.75
HDAC8 Q9BY41 2/20 0.75
HDAC6 Q9UBN7 2/20 0.75
HDAC9 Q9UKV0 2/20 0.75
HDAC5 Q9UQL6 2/20 0.75
PDGFRA P16234 4/20 0.71
EGFR P00533 2/20 0.71
ERBB2 P04626 1/20 0.71
LCK P06239 1/20 0.71
FYN P06241 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714756 0.96 ABL1 (0.76) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL1096984 0.94 ABL1 (0.75) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL4087640 0.93 ABL1 (0.82) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL715666 0.93 ABL1 (0.76) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL3794413 0.93 ABL1 (0.76) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL5254826 0.92 ABL1 (0.72) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL715902 0.92 ABL1 (0.75) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL715237 0.92 ABL1 (0.75) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL716396 0.92 ABL1 (0.75) ABL1BCRPDGFRBHDAC3KDR
SCHEMBL714758 0.91 ABL1 (0.73) ABL1BCRPDGFRBHDAC3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100491374-C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2009-05-27 CN claimed
US-7423055-B2 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE (FR) 2008-09-09 US claimed
EP-1525200-B1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2007-10-10 EP claimed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN claimed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-8450302-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2013-05-28 US disclosed
US-8450302-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2013-05-28 US disclosed
WO-2005112920-A1 USE OF MAST CELLS INHIBITORS FOR TREATING PATIENTS EXPOSED TO CHEMICAL OR BIOLOGICAL WEAPONS AB SCIENCE (FR) 2005-12-01 WO disclosed
WO-2005102325-A1 USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY AB SCIENCE (FR) 2005-11-03 WO disclosed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN disclosed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP disclosed
WO-2005016323-A2 USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES AB SCIENCE (FR) 2005-02-24 WO disclosed
WO-2004096225-A2 USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA AB SCIENCE (FR) 2004-11-11 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 ABL1 251/4885BCR 678/4885PDGFRB 149/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B ABL1 22/4885BCR 167/4885PDGFRB 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.